Legal notice

You are currently on the website published in the frame of the Net4CGD European consortium by Genethon, a French not-for-profit association organised under the French law of July 1, 1901 and located 1bis rue de l’Internationale, 91002 Evry, France, N° SIREN 402 187 520, Tél: +33(0)1 69 47 28 28. The publishing editor is Anne Galy, from Genethon.
The managing editor is Elodie Noël from Finovatis, a partner in the Net4CGD consortium. Finovatis is a company with a capital of 250.000€, registered with the Registry of Commerce & Companies of Lyon under number n°481 118 388 (adress 68 Cours Lafayette Immeuble Lafayette 69003 Lyon Cedex 03, France Tél. : +33(0)4 78 54 79 40 Fax : +33(0)4 72 33 65 17.
The Website is hosted by Claranet SAS, 18-20, rue du Faubourg du Temple 75011, Paris, France, Tel : +33 (0)826 007 656.

This website :

  • is dedicated to scientific and public communities,
  • presents scientific and medical information on the Net4CGD research program, a large-scale integrating project that has received funding from the European Community’s Seventh Framework Programme (FP7-HEALTH-2012-INNOVATION-1) under grant agreement  305011,
  • ensures the proper promotion and sharing of Net4CGD consortium results and outputs.

Copyright over text and images :

Users of the Net4CGD website agree to respect the intellectual property rights over the content offered on the website and will not :

  • copy, summarize, modify, alter or redistribute, without prior permission from Finovatis any article, title, application, software, logo, brand name, information, illustration or photograph other than for strictly private purposes; this includes copying for professional purposes and mass distribution;
  • reproduce all or part of the website on another website or internal company network.

Photo credits :

  • Inserm Serimedis
    • Cell producing a lentivirus - author: Jean-Claude Chermann
    • Monocyte - author : Dimitri Dantchev
    • Circulating monocytes - author: Andrea Cimarelli & Colette Dezutter,
    • Pulmonary aspergillosis - author : Loïc Guillevin,
    • Neutrophil killing bacteria, neutrophil, blood neutrophil - author: Elisabeth Cramer,
    • Removal of bone marrow, lentivirus structure - author : Michel Depardieu,
    • Blood granulocyte surrounded by erythrocytes - author: Claude Féo,
    • Aspergillus fumigates - author: Eveline Guého,
  • Schema of Gene therapy for X-CGD - Courtesy to Manuel Grez
  • Hematopoietic colonies – author AFM/Genethon
  • Laboratory tests – author AFM/Genethon
  • Clinical-grade gene therapy vector– author AFM/Genethon

Graphical and technical design :

Elle&La :  8 rue Lemercier, 75017 Paris, France

XCGD Multicentric European Study - Q&A

As part of the NET4CGD dissemination strategy and in order to provide information to patients, a Q&A titled "New gene therapy trial for X-CGD" has been created that can be found on the NET4CGD website under the "NET4CGD Project" tab.

NET4CGD Results In Brief

As the European Commission's primary public repository and portal to disseminate information on all EU-funded research projects and their results in the broadest sense, CORDIS has published a summary on the NET4CGD project. This project summary  is available in several languages (French, English, German, Spanish, Italian and Polish) that can be found on the NET4CGD website under the "NET4CGD Project" tab.

Net4CGD new scientific article to be published in Journal of Allergy and Clinical Immunology - 2016

Net4CGD scientists in Frankfurt, Paris and London report that hyperinflammation in CGD leads to impairment of hematopoietic stem cell functions in the prestigious Journal of Allergy and Clinical Immunology. Persistent chronic inflammation in CGD is associated with hematopoietic proliferative stress leading to a decrease in the functional activity of hematopoietic stem cells. Proactive treatment of CGD patients with anti-inflammatory drugs might therefore reduce chronic sterile inflammation in CGD and in addition could have an impact on the quantity and quality of hematopoietic stem cells available for autologous gene therapy.

The article will be published in 2016.